Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02840357
Other study ID # PWIS2
Secondary ID
Status Completed
Phase N/A
First received July 19, 2016
Last updated March 29, 2018
Start date July 2016
Est. completion date December 1, 2017

Study information

Verified date March 2018
Source University of Guelph
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main purpose of this study is to determine the effect of consumption of purple wheat anthocyanin-rich products for eight weeks by human participants with an elevated level of chronic inflammation, on oxidative stress and inflammatory responses as measured by select plasma biomarkers.


Description:

This study will investigate the effect of daily consumption of purple wheat bran-enriched wholegrain convenience bars, for 8 weeks on inflammation and oxidative stress biomarkers and plasma antioxidant capacity. This study is a randomized, parallel arm study with 20 men and 20 women who will adhere to a low anthocyanin and low phenolic aid diet for the duration of the study. The participants will be randomly divided into two groups, using stratification for matching sex and screening hs-CRP level to be equally distributed in each group, and assigned to either the treatment group or control group. Both group will have a 10 day diet run-in period where consumption of foods rich in anthocyanins and phenolic acids will be limited. Both groups will consume 4 servings of wheat products per day for 8 weeks and will replace 4 grain servings from their typical daily intake with the study treatment products. Fasting blood samples will be collected during three study visits, including baseline, for the analysis of inflammatory and oxidative stress biomarkers and plasma antioxidant capacity. The plasma metabolites of anthocyanins and phenolic acids will also be determined.


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date December 1, 2017
Est. primary completion date July 1, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- BMI = 25 kg/m2 and/or Waist circumference =102 cm (men) and =88 cm (women)

- hs-CRP: = 1.0 mg/L at time of screening

- Stable (>3 months) and consistent use of all prescribed medications and/or supplements

- Non- to moderate alcohol consumer (i.e. less than 5 drinks per sitting and no more than 14 per week)

- Not taking any antibiotics within the last 3 months, or planning to take antibiotics within the next 6 months

Exclusion Criteria:

- Pregnant or breastfeeding females

- Lifetime history of any acute medical event, including but not limited to, heart attack or stroke

- Occasional or intermittent smoker (includes but not limited to tobacco and cannabis)

- Consistent smoker of <1 year

- Recent diagnosis (within 6 months) of a serious medical condition, including but not limited to, cancer, diabetes, heart disease or hepatitis

- Recent history (within 6 months) of a clinically significant psychiatric disorder, other than mild depression

- Any disorder of the gastrointestinal system or food intolerances, including but not limited to, inflammatory bowel disease or Celiac disease

- Any food allergies or any life-threatening allergies, food or otherwise

- Regular recreational drug use of more than once per week, including but not limited to cannabis, magic mushrooms, ecstasy etc

- Difficulty providing blood samples

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Purple Wheat Convenience Bars
Whole grain convenience bars manufactured with purple wheat
Control Wheat Convenience Bars
Whole grain convenience bars manufactured with ordinary wheat

Locations

Country Name City State
Canada Human Nutraceutical Research Unit, University of Guelph Guelph Ontario

Sponsors (1)

Lead Sponsor Collaborator
University of Guelph

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Serum concentration of inflammatory biomarker (hs-CRP) Fasting (0 hours)
Secondary Plasma concentration of lipids Fasting (0 hours)
Secondary Plasma concentration of inflammatory biomarkers Fasting (0 hours)
Secondary Plasma concentration of total antioxidant capacity Fasting (0 hours)
Secondary Plasma concentrations of anthocyanin metabolites and phenolic acids Fasting (0 hours)
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1